Skip to content
DataLookout
Menu

ziMyGNCT06055959

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

StatusRecruiting
PhasePhase 2/3
Primary completion (estimated)

At risk: Primary completion moved at least 5 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 32 versions: 31 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Primary completion pushed from Nov 16, 2026 to May 12, 2027
    • Study completion pushed from Dec 25, 2026 to Jun 22, 2027
  2. Notable Eligibility criteria expanded, about 11 words
    • Secondary endpoints: details revised at 8 of 9 entries
    • Site details revised at 1 of 9 sites
  3. Minor Site details revised at 2 of 9 sitesv30
  4. Minor Site details revised at 1 of 9 sitesv29
  5. Minor Site details revised at 1 of 9 sitesv28
Show 25 earlier versionsHide 25 earlier versions
  1. Minor Site details revised at 1 of 9 sitesv27
  2. Minor Site details revised at 2 of 9 sitesv26
  3. Minor Site details revised at 1 of 9 sitesv25
  4. Minor Site details revised at 1 of 9 sitesv24
  5. Minor Site details revised at 1 of 9 sitesv23
  6. Minor Site details revised at 1 of 9 sitesv22
  7. Minor Site details revised at 1 of 9 sitesv21
  8. Minor Site details revised at 1 of 9 sitesv20
  9. Minor Study sites: 8 to 9v19
  10. Minor Study sites: 7 to 8v17
  11. Minor Study sites: 6 to 7v16
  12. Minor Study sites: 5 to 6v15
  13. Minor Start date changed from estimate of Oct 15, 2024 to Oct 16, 2024v14
  14. Minor Start date: Sep 16, 2024 to Oct 15, 2024v13
  15. Notable Start date: Jul 15, 2024 to Sep 16, 2024
    • Primary completion date: Oct 26, 2026 to Nov 16, 2026
    • Study completion date: Dec 4, 2026 to Dec 25, 2026
    v12
  16. Notable Start date: Jun 11, 2024 to Jul 15, 2024v11
  17. Minor Study sites: 4 to 5v10
  18. Notable Start date: May 7, 2024 to Jun 11, 2024v9
  19. Minor Study sites: 3 to 4v8
  20. Minor Start date: Apr 25, 2024 to May 7, 2024v7
  21. Minor Study sites: 1 to 3v6
  22. Notable Start date: Mar 18, 2024 to Apr 25, 2024v5
  23. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jan 31, 2024 to Mar 18, 2024
    • Study sites: 0 to 1
    v4
  24. Notable Eligibility criteria expanded, about 46 words
    • Start date: Jan 2024 to Jan 31, 2024
    v3
  25. Notable Start date: Sep 29, 2023 to Jan 2024v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Plasma concentrations of zilucoplan (ZLP) sampled at Week 4 (Day 29)
Timeframe: Week 4 (Day 29)
Change from Baseline in sheep red blood cell (sRBC) lysis at Week 4 (Day 29)
Timeframe: Week 4 (Day 29)
Change from Baseline in complement component 5 (C5) levels at Week 4 (Day 29)
Timeframe: Week 4 (Day 29)

Secondary (9)

Occurence of treatment-emergent adverse events (TEAEs) during the course of the study
Occurrence of treatment-emergent serious adverse events (TESAEs)
Occurrence of TEAEs leading to permanent withdrawal of investigational medicinal product (IMP)
Occurrence of treatment-emergent infections
Occurrence of antidrug antibody (ADA) and anti- polyethylene glycol (PEG) antibodies at Week 4 (Day 29)
Show 4 moreShow less
Change in MG-activities of daily living (MG-ADL) score from Baseline to Week 4 (Day 29).
Change in Quantitative MG (QMG) score from Baseline to Week 4 (Day 29)
Myasthenia Gravis Foundation of America Post-Interventional Status (MGFA-PIS) at Week 4 (Day 29)
Change in Pediatric Quality of Life Inventory (PedsQoL), Version 4 domain scores from Baseline to Week 4 (Day 29)

Arms and interventions

Zilucoplan ArmExperimental

Study participants will receive zilucoplan in pre-defined dose based on their weight.

Drugs: Zilucoplan

Sites

9 sites in 5 countries

Poland 2, South Korea 2, United Kingdom 2, United States 2, Italy 1